IP Library › Granted Patent US 7,273,849
Granted Patent B2
US 7,273,849 · App. 11/116,319 · Granted Sep 25, 2007

ProapolipoproteinA-I mutant and pharmaceutical composition comprising the same for prevention and treatment of atherosclerosis and hyperlipidemia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,273,849
App. No.
11/116,319
Granted
Sep 25, 2007
Kind
B2
Abstract

The proapoA-I mutants of the present invention exhibit superior LDL-antioxidant activities over the wild-type proapoA-I and higher efficiencies for delivering cholesterol to hepatocytes than the previously reported apoA-I-R173C, and thus they can be effectively used for prevention and treatment of hyperlipidemia or atherosclerosis.

Claims (6)

1. An isolated polypeptide consisting SEQ ID NO:21.

2. An isolated polypeptide comprising of SEQ ID NO:21.

3. A pharmaceutical composition comprising the polypeptide of claim 1 or 2 for treatment of hyperlipidemia.

4. A pharmaceutical composition comprising the polypeptide of claim 1 or 2 for treatment of atherosclerosis.

5. A method of treating hyperlipidemia comprising administering the pharmaceutical composition of claim 3 .

6. A method of treating atherosclerosis comprising administering the pharmaceutical composition of claim 4 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2009
From: CHO, KYUNG-HYUN
To: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YEUNGNAM UNIVERSITY
Reel/Frame 022354/0362 →
Priority Claims (1)
KR 10-2004-0048354 · Jun 25, 2004 · national
Continuity (1)
Related Publication 20050287636A1 · Dec 29, 2005